Effect of risedronate on bone in renal transplant recipients

Maria Coco, James M. Pullman, Hillel W. Cohen, Sally Lee, Craig Shapiro, Clemencia Solorzano, Stuart M. Greenstein, Daniel Glicklich

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Bisphosphonates may prevent or treat the bone loss promoted by the immunosuppressive regimens used in renal transplantation. Risedronate is a commonly used third-generation amino-bisphosphonate, but little is known about its effects on the bone health of renal transplant recipients. We randomly assigned 42 new living-donor kidney recipients to either 35 mg of risedronate weekly or placebo for 12 months. We obtained bone biopsies at the time of renal transplant and after 12 months of protocol treatment. Treatment with risedronate did not affect bone mineral density (BMD) in the overall cohort. In subgroup analyses, it tended to preserve BMD in female participants but did not significantly affect the BMD of male participants. Risedronate did associate with increased osteoid volume and trabecular thickness in male participants, however. Therewas no evidence for the development of adynamic bone disease. In summary, further study is needed before the use of prophylactic bisphosphonates to attenuate bone loss can be recommended in renal transplant recipients.

Original languageEnglish (US)
Pages (from-to)1426-1437
Number of pages12
JournalJournal of the American Society of Nephrology
Volume23
Issue number8
DOIs
StatePublished - Aug 2012

Fingerprint

Diphosphonates
Bone Density
Kidney
Bone and Bones
Living Donors
Bone Diseases
Immunosuppressive Agents
Clinical Protocols
Kidney Transplantation
Placebos
Transplants
Biopsy
Risedronate Sodium
Transplant Recipients
Health
Therapeutics

ASJC Scopus subject areas

  • Nephrology

Cite this

Effect of risedronate on bone in renal transplant recipients. / Coco, Maria; Pullman, James M.; Cohen, Hillel W.; Lee, Sally; Shapiro, Craig; Solorzano, Clemencia; Greenstein, Stuart M.; Glicklich, Daniel.

In: Journal of the American Society of Nephrology, Vol. 23, No. 8, 08.2012, p. 1426-1437.

Research output: Contribution to journalArticle

Coco, Maria ; Pullman, James M. ; Cohen, Hillel W. ; Lee, Sally ; Shapiro, Craig ; Solorzano, Clemencia ; Greenstein, Stuart M. ; Glicklich, Daniel. / Effect of risedronate on bone in renal transplant recipients. In: Journal of the American Society of Nephrology. 2012 ; Vol. 23, No. 8. pp. 1426-1437.
@article{9fdd3a470ccd42bc9f08fe8140654dd2,
title = "Effect of risedronate on bone in renal transplant recipients",
abstract = "Bisphosphonates may prevent or treat the bone loss promoted by the immunosuppressive regimens used in renal transplantation. Risedronate is a commonly used third-generation amino-bisphosphonate, but little is known about its effects on the bone health of renal transplant recipients. We randomly assigned 42 new living-donor kidney recipients to either 35 mg of risedronate weekly or placebo for 12 months. We obtained bone biopsies at the time of renal transplant and after 12 months of protocol treatment. Treatment with risedronate did not affect bone mineral density (BMD) in the overall cohort. In subgroup analyses, it tended to preserve BMD in female participants but did not significantly affect the BMD of male participants. Risedronate did associate with increased osteoid volume and trabecular thickness in male participants, however. Therewas no evidence for the development of adynamic bone disease. In summary, further study is needed before the use of prophylactic bisphosphonates to attenuate bone loss can be recommended in renal transplant recipients.",
author = "Maria Coco and Pullman, {James M.} and Cohen, {Hillel W.} and Sally Lee and Craig Shapiro and Clemencia Solorzano and Greenstein, {Stuart M.} and Daniel Glicklich",
year = "2012",
month = "8",
doi = "10.1681/ASN.2011060623",
language = "English (US)",
volume = "23",
pages = "1426--1437",
journal = "Journal of the American Society of Nephrology : JASN",
issn = "1046-6673",
publisher = "American Society of Nephrology",
number = "8",

}

TY - JOUR

T1 - Effect of risedronate on bone in renal transplant recipients

AU - Coco, Maria

AU - Pullman, James M.

AU - Cohen, Hillel W.

AU - Lee, Sally

AU - Shapiro, Craig

AU - Solorzano, Clemencia

AU - Greenstein, Stuart M.

AU - Glicklich, Daniel

PY - 2012/8

Y1 - 2012/8

N2 - Bisphosphonates may prevent or treat the bone loss promoted by the immunosuppressive regimens used in renal transplantation. Risedronate is a commonly used third-generation amino-bisphosphonate, but little is known about its effects on the bone health of renal transplant recipients. We randomly assigned 42 new living-donor kidney recipients to either 35 mg of risedronate weekly or placebo for 12 months. We obtained bone biopsies at the time of renal transplant and after 12 months of protocol treatment. Treatment with risedronate did not affect bone mineral density (BMD) in the overall cohort. In subgroup analyses, it tended to preserve BMD in female participants but did not significantly affect the BMD of male participants. Risedronate did associate with increased osteoid volume and trabecular thickness in male participants, however. Therewas no evidence for the development of adynamic bone disease. In summary, further study is needed before the use of prophylactic bisphosphonates to attenuate bone loss can be recommended in renal transplant recipients.

AB - Bisphosphonates may prevent or treat the bone loss promoted by the immunosuppressive regimens used in renal transplantation. Risedronate is a commonly used third-generation amino-bisphosphonate, but little is known about its effects on the bone health of renal transplant recipients. We randomly assigned 42 new living-donor kidney recipients to either 35 mg of risedronate weekly or placebo for 12 months. We obtained bone biopsies at the time of renal transplant and after 12 months of protocol treatment. Treatment with risedronate did not affect bone mineral density (BMD) in the overall cohort. In subgroup analyses, it tended to preserve BMD in female participants but did not significantly affect the BMD of male participants. Risedronate did associate with increased osteoid volume and trabecular thickness in male participants, however. Therewas no evidence for the development of adynamic bone disease. In summary, further study is needed before the use of prophylactic bisphosphonates to attenuate bone loss can be recommended in renal transplant recipients.

UR - http://www.scopus.com/inward/record.url?scp=84864834951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864834951&partnerID=8YFLogxK

U2 - 10.1681/ASN.2011060623

DO - 10.1681/ASN.2011060623

M3 - Article

C2 - 22797188

AN - SCOPUS:84864834951

VL - 23

SP - 1426

EP - 1437

JO - Journal of the American Society of Nephrology : JASN

JF - Journal of the American Society of Nephrology : JASN

SN - 1046-6673

IS - 8

ER -